NO333143B1 - Nye fettsyreanaloger for behandling av diabetes - Google Patents
Nye fettsyreanaloger for behandling av diabetes Download PDFInfo
- Publication number
- NO333143B1 NO333143B1 NO20005462A NO20005462A NO333143B1 NO 333143 B1 NO333143 B1 NO 333143B1 NO 20005462 A NO20005462 A NO 20005462A NO 20005462 A NO20005462 A NO 20005462A NO 333143 B1 NO333143 B1 NO 333143B1
- Authority
- NO
- Norway
- Prior art keywords
- integer
- diabetes
- accordance
- fatty acid
- pharmaceutical material
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 52
- 239000000194 fatty acid Substances 0.000 title claims abstract description 52
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 52
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 34
- 230000002265 prevention Effects 0.000 claims abstract description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 65
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 239000008103 glucose Substances 0.000 claims description 37
- 102000004877 Insulin Human genes 0.000 claims description 32
- 108090001061 Insulin Proteins 0.000 claims description 32
- 229940125396 insulin Drugs 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000011669 selenium Substances 0.000 claims description 11
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 201000008980 hyperinsulinism Diseases 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 102000003746 Insulin Receptor Human genes 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 description 88
- 241000700159 Rattus Species 0.000 description 64
- 150000001875 compounds Chemical class 0.000 description 38
- 230000000694 effects Effects 0.000 description 29
- 235000005911 diet Nutrition 0.000 description 25
- 230000037213 diet Effects 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 238000007254 oxidation reaction Methods 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
- 230000002438 mitochondrial effect Effects 0.000 description 16
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 150000002632 lipids Chemical group 0.000 description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 9
- 241000700157 Rattus norvegicus Species 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 235000009200 high fat diet Nutrition 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 235000015278 beef Nutrition 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003760 tallow Substances 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 230000001610 euglycemic effect Effects 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 230000000910 hyperinsulinemic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 3
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 3
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 3
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- -1 gums Substances 0.000 description 3
- 230000006362 insulin response pathway Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002627 tracheal intubation Methods 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XOMRRQXKHMYMOC-OAQYLSRUSA-N O-palmitoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-OAQYLSRUSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000021053 average weight gain Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000081 effect on glucose Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004322 lipid homeostasis Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000006286 nutrient intake Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000011680 zucker rat Methods 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Saccharide Compounds (AREA)
- Edible Oils And Fats (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20005462A NO333143B1 (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av diabetes |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NO1998/000143 WO1999058120A1 (en) | 1998-05-08 | 1998-05-08 | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| PCT/NO1999/000136 WO1999058122A1 (en) | 1998-05-08 | 1999-04-23 | Novel fatty analogues for the treatment of diabetes |
| NO20005462A NO333143B1 (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005462D0 NO20005462D0 (no) | 2000-10-30 |
| NO20005462L NO20005462L (no) | 2001-01-08 |
| NO333143B1 true NO333143B1 (no) | 2013-03-18 |
Family
ID=19907879
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005463A NO20005463L (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av primær og sekundær restenose |
| NO20005462A NO333143B1 (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av diabetes |
| NO20005461A NO20005461L (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005463A NO20005463L (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av primær og sekundær restenose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005461A NO20005461L (no) | 1998-05-08 | 2000-10-30 | Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US6365628B1 (de) |
| EP (5) | EP1075258B1 (de) |
| JP (3) | JP5057003B2 (de) |
| KR (3) | KR100701502B1 (de) |
| CN (3) | CN1245157C (de) |
| AT (5) | ATE336239T1 (de) |
| AU (4) | AU7240398A (de) |
| BR (2) | BR9910296A (de) |
| CA (3) | CA2331408C (de) |
| DE (5) | DE69932645D1 (de) |
| DK (3) | DK1075259T3 (de) |
| ES (3) | ES2207253T3 (de) |
| NO (3) | NO20005463L (de) |
| NZ (3) | NZ508047A (de) |
| PT (2) | PT1075259E (de) |
| RU (3) | RU2221558C2 (de) |
| WO (4) | WO1999058120A1 (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| AU784588B2 (en) * | 1999-09-17 | 2006-05-04 | Peplin Biolipids Pty Ltd | Anti-inflammatory nitro- and thia- fatty acids |
| AUPQ291499A0 (en) * | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
| CA2388754C (en) * | 1999-10-13 | 2010-07-13 | Marco A. Chacon | Therapeutic intervention to mimic the effect of caloric restriction |
| NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| NO20003591L (no) * | 2000-07-13 | 2002-01-14 | Thia Medica As | Fettsyreanaloger for behandling av kreft |
| NO20004844L (no) * | 2000-09-27 | 2002-05-10 | Thia Medica As | Fettsyre analoger for behandling av proliferative hudsykdommer |
| NO20006008L (no) * | 2000-11-28 | 2002-05-29 | Thia Medica As | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer |
| DE10115740A1 (de) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
| IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| ES2186576B1 (es) * | 2001-10-11 | 2004-09-16 | Universitat De Les Illes Balears | Acido 2-hidroxioleico para utilizar como medicamento. |
| US6908632B1 (en) | 2002-04-19 | 2005-06-21 | Pharmanex, Llc | Blood glucose modulating compositions and methods |
| JP4433496B2 (ja) * | 2002-05-28 | 2010-03-17 | 味の素株式会社 | Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用 |
| RU2331649C2 (ru) * | 2002-06-20 | 2008-08-20 | Ай-Си Ви-И-Си Лимитед | Серосодержащие фосфолипидные производные, содержащая их фармацевтическая композиция, их применение для лечения заболеваний и способ их получения |
| US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US7045547B2 (en) * | 2002-08-20 | 2006-05-16 | University Of Delaware | Acyl-CoA dehydrogenase allenic inhibitors |
| EP1545532A2 (de) | 2002-09-06 | 2005-06-29 | Janssen Pharmaceutica N.V. | Heterozyklische verbindungen |
| BR0314799A (pt) * | 2002-09-27 | 2005-07-26 | Market Biosciences Corp | Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico |
| KR20050071565A (ko) * | 2002-10-10 | 2005-07-07 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도 |
| FR2850650B1 (fr) * | 2003-01-31 | 2005-03-25 | Genfit S A | Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures |
| FR2850869B1 (fr) * | 2003-02-12 | 2005-03-25 | Genfit S A | Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures |
| CA2515368A1 (en) | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| RU2356247C2 (ru) * | 2003-03-18 | 2009-05-27 | Новартис Аг | Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор |
| WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
| US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| JP2008501110A (ja) * | 2004-05-28 | 2008-01-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 覚醒ラットにおける新しい静脈内薬物投与および血液サンプリングモデル |
| DE102004034640A1 (de) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Verfahren zur systemischen Biokorrektur eines Organismus |
| RU2394598C2 (ru) * | 2004-07-19 | 2010-07-20 | Тиа Медика Ас | Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот |
| RU2272628C1 (ru) * | 2004-07-19 | 2006-03-27 | Илья Николаевич Медведев | Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме |
| EP1784223A2 (de) * | 2004-07-19 | 2007-05-16 | Thia Medica AS | Zusammensetzung enthaltend pflanzen- oder fischöl und nicht-oxidierbaren fettsäuren |
| NO324534B1 (no) * | 2004-07-19 | 2007-11-19 | Thia Medica As | Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav |
| WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
| US7288525B2 (en) * | 2004-12-28 | 2007-10-30 | The Research Foundation Of State University Of New York | Method for lowering serum homocysteine |
| WO2006088875A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels |
| EP1888728A4 (de) * | 2005-05-04 | 2010-07-14 | Pronova Biopharma Norge As | Fettsäureanaloge, d. h. dha-derivate zur verwendung als medikament |
| RU2441061C2 (ru) * | 2005-05-04 | 2012-01-27 | Пронова Биофарма Норге Эс. | Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств |
| US7586003B2 (en) * | 2005-07-14 | 2009-09-08 | Zinpro Corporation | Derivatives of seleno-amino acids |
| NO20053519L (no) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Anvendelse av forbindelser som omfatter fettsyrer |
| NO20055541L (no) * | 2005-11-23 | 2007-05-24 | Berge Biomed As | Use of fatty acid analogues |
| GB0605900D0 (en) * | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
| US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
| SI2724722T1 (sl) | 2006-10-20 | 2017-07-31 | Neurendo Pharma, Llc | Postopek za obnovitev učinka inkretina |
| MX2009004337A (es) * | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Compuestos lipidos omega-3. |
| JP5552313B2 (ja) * | 2006-11-01 | 2014-07-16 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物 |
| US20080221115A1 (en) * | 2007-02-26 | 2008-09-11 | Liat Hayardeny-Nisimov | Use of long-chain alcohol derivatives for the treatment of alopecia areata |
| WO2008106092A1 (en) * | 2007-02-26 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
| EP2214481B1 (de) | 2007-10-15 | 2019-05-01 | United Animal Health, Inc. | Verfahren zur erhöhung der leistung von nachkommen |
| EP2217558A1 (de) * | 2007-10-31 | 2010-08-18 | Pronova Biopharma Norge AS | Neue dha-derivate und ihre verwendung als medikamente |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| CA2722114A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | 4-trimethylammonio-butyrates as cpt2 inhibitors |
| EP2147910A1 (de) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Neue Lipid-Verbindungen |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| WO2010033878A2 (en) | 2008-09-19 | 2010-03-25 | David Brown | Solute concentration measurement device and related methods |
| NZ596386A (en) | 2009-05-08 | 2014-01-31 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| US20110152770A1 (en) | 2009-07-30 | 2011-06-23 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| US20130209550A1 (en) | 2010-07-28 | 2013-08-15 | Life Technologies Corporation | Anti-Viral Azide Containing Compounds |
| UA111475C2 (uk) | 2010-11-05 | 2016-05-10 | Пронова Байофарма Нордж Ас | Способи лікування із застосуванням ліпідних сполук |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| WO2014132134A1 (en) | 2013-02-28 | 2014-09-04 | Pronova Biopharma Norge As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| AU2014229506B2 (en) | 2013-03-11 | 2017-04-13 | Nobesita As | Natural lipids containing non-oxidizable fatty acids |
| EP2983658B1 (de) | 2013-03-11 | 2024-05-01 | Sciadonics, Inc. | Lipidzusammensetzungen mit bioaktiven fettsäuren |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| RU2522224C1 (ru) * | 2013-08-06 | 2014-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" | Способ лечения острого гепатоза у кошек |
| WO2016073615A1 (en) | 2014-11-07 | 2016-05-12 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
| KR20240033300A (ko) | 2015-04-28 | 2024-03-12 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
| US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
| WO2019083816A1 (en) * | 2017-10-23 | 2019-05-02 | Epitracker, Inc. | FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME |
| EP3720431B1 (de) | 2017-12-06 | 2024-10-30 | Basf As | Fettsäurederivate zur behandlung von nicht-alkoholischer steatohepatitis |
| CA3099482A1 (en) | 2018-05-23 | 2019-11-28 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| WO2020146263A1 (en) | 2019-01-09 | 2020-07-16 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| EP3934639A4 (de) | 2019-03-04 | 2023-01-11 | Epitracker, Inc. | Fettsäureanaloge und deren verwendung zur behandlung von kognitiven beeinträchtigungen, verhaltenszuständen und chronischen schmerzen |
| JP2024539823A (ja) | 2021-11-03 | 2024-10-31 | エピトラッカー インコーポレイテッド | 老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン |
| KR20250043868A (ko) | 2023-09-22 | 2025-03-31 | 건국대학교 산학협력단 | 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59175425A (ja) * | 1983-03-25 | 1984-10-04 | Otsuka Pharmaceut Co Ltd | 脳卒中予防剤 |
| GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
| US6063581A (en) * | 1992-01-22 | 2000-05-16 | Axis-Shield Asa | Immunoassay for homocysteine |
| AU6277396A (en) * | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| NO952796D0 (no) * | 1995-07-14 | 1995-07-14 | Rolf Berge | Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater |
| DE69622722T2 (de) * | 1996-11-20 | 2003-02-27 | N.V. Nutricia, Zoetermeer | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms |
| AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
-
1998
- 1998-05-08 AU AU72403/98A patent/AU7240398A/en not_active Abandoned
- 1998-05-08 WO PCT/NO1998/000143 patent/WO1999058120A1/en not_active Ceased
-
1999
- 1999-04-23 AT AT02024616T patent/ATE336239T1/de not_active IP Right Cessation
- 1999-04-23 AU AU49367/99A patent/AU762790B2/en not_active Ceased
- 1999-04-23 DK DK99933293T patent/DK1075259T3/da active
- 1999-04-23 EP EP99933292A patent/EP1075258B1/de not_active Expired - Lifetime
- 1999-04-23 US US09/700,062 patent/US6365628B1/en not_active Expired - Lifetime
- 1999-04-23 WO PCT/NO1999/000135 patent/WO1999058121A1/en not_active Ceased
- 1999-04-23 PT PT99933293T patent/PT1075259E/pt unknown
- 1999-04-23 DK DK99933292T patent/DK1075258T3/da active
- 1999-04-23 CA CA002331408A patent/CA2331408C/en not_active Expired - Fee Related
- 1999-04-23 AT AT99933293T patent/ATE245416T1/de not_active IP Right Cessation
- 1999-04-23 KR KR1020007012281A patent/KR100701502B1/ko not_active Expired - Fee Related
- 1999-04-23 CA CA002331395A patent/CA2331395C/en not_active Expired - Fee Related
- 1999-04-23 NZ NZ508047A patent/NZ508047A/en not_active IP Right Cessation
- 1999-04-23 DE DE69932645T patent/DE69932645D1/de not_active Expired - Lifetime
- 1999-04-23 DE DE69909775T patent/DE69909775T2/de not_active Expired - Lifetime
- 1999-04-23 NZ NZ508045A patent/NZ508045A/en not_active IP Right Cessation
- 1999-04-23 DE DE69910559T patent/DE69910559T2/de not_active Expired - Lifetime
- 1999-04-23 EP EP99933293A patent/EP1075259B1/de not_active Expired - Lifetime
- 1999-04-23 ES ES99933292T patent/ES2207253T3/es not_active Expired - Lifetime
- 1999-04-23 RU RU2000131221/14A patent/RU2221558C2/ru not_active IP Right Cessation
- 1999-04-23 JP JP2000547972A patent/JP5057003B2/ja not_active Expired - Fee Related
- 1999-04-23 DE DE69932864T patent/DE69932864D1/de not_active Expired - Lifetime
- 1999-04-23 US US09/700,061 patent/US6441036B1/en not_active Expired - Lifetime
- 1999-04-23 EP EP02024616A patent/EP1285652B1/de not_active Expired - Lifetime
- 1999-04-23 KR KR1020007012282A patent/KR100701503B1/ko not_active Expired - Fee Related
- 1999-04-23 WO PCT/NO1999/000136 patent/WO1999058122A1/en not_active Ceased
- 1999-04-23 EP EP02024388A patent/EP1284139B1/de not_active Expired - Lifetime
- 1999-04-23 RU RU2000131222/15A patent/RU2219920C2/ru not_active IP Right Cessation
- 1999-04-23 AT AT02024388T patent/ATE334666T1/de not_active IP Right Cessation
- 1999-04-23 BR BR9910296-0A patent/BR9910296A/pt not_active IP Right Cessation
- 1999-04-23 AU AU49366/99A patent/AU762792B2/en not_active Ceased
- 1999-04-23 PT PT99933292T patent/PT1075258E/pt unknown
- 1999-04-23 BR BR9910297-8A patent/BR9910297A/pt not_active Application Discontinuation
- 1999-04-23 ES ES99933293T patent/ES2204142T3/es not_active Expired - Lifetime
- 1999-04-23 CN CNB998059668A patent/CN1245157C/zh not_active Expired - Fee Related
- 1999-04-23 JP JP2000547973A patent/JP2002514595A/ja active Pending
- 1999-04-23 AT AT99933292T patent/ATE247464T1/de not_active IP Right Cessation
- 1999-04-23 CN CNB998059684A patent/CN1223343C/zh not_active Expired - Fee Related
- 1999-05-07 NZ NZ508046A patent/NZ508046A/en not_active IP Right Cessation
- 1999-05-07 US US09/674,982 patent/US6417232B1/en not_active Expired - Lifetime
- 1999-05-07 JP JP2000547974A patent/JP4465672B2/ja not_active Expired - Fee Related
- 1999-05-07 KR KR1020007012283A patent/KR100822077B1/ko not_active Expired - Fee Related
- 1999-05-07 CA CA002331393A patent/CA2331393C/en not_active Expired - Fee Related
- 1999-05-07 RU RU2000131220/15A patent/RU2223095C2/ru not_active IP Right Cessation
- 1999-05-07 AT AT99940723T patent/ATE306916T1/de not_active IP Right Cessation
- 1999-05-07 ES ES99940723T patent/ES2251218T3/es not_active Expired - Lifetime
- 1999-05-07 DE DE69927805T patent/DE69927805T2/de not_active Expired - Fee Related
- 1999-05-07 WO PCT/NO1999/000149 patent/WO1999058123A2/en not_active Ceased
- 1999-05-07 EP EP99940723A patent/EP1075260B1/de not_active Expired - Lifetime
- 1999-05-07 AU AU54517/99A patent/AU761355B2/en not_active Ceased
- 1999-05-07 CN CNB998059676A patent/CN1244323C/zh not_active Expired - Fee Related
- 1999-05-07 DK DK99940723T patent/DK1075260T3/da active
-
2000
- 2000-10-30 NO NO20005463A patent/NO20005463L/no not_active Application Discontinuation
- 2000-10-30 NO NO20005462A patent/NO333143B1/no not_active IP Right Cessation
- 2000-10-30 NO NO20005461A patent/NO20005461L/no not_active Application Discontinuation
-
2002
- 2002-05-17 US US10/151,203 patent/US7026356B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333143B1 (no) | Nye fettsyreanaloger for behandling av diabetes | |
| EP1037624B1 (de) | Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes | |
| US7015249B1 (en) | Methods and compositions for treating diabetes | |
| Kollman‐Bauerly et al. | The role of eicosanoids in the process of adaptation following massive bowel resection in the rat | |
| EP2090176B1 (de) | Wirkstoff zur Verbesserung der postprandialen Hyperglykämie | |
| HK1034909B (en) | Novel fatty analogues for the treatment of diabetes | |
| HK1034912B (en) | Novel fatty analogues for the treatment of obesity | |
| HK1051967A (en) | Novel fatty acid analogues for the treatment of fatty liver | |
| HK1053265A (en) | Novel fatty acid analogues for the treatment of hypertension | |
| MXPA00010998A (en) | Novel fatty analogues for the treatment of diabetes | |
| Beck-Nielsen et al. | Treatment of NIDDM patients with peroral antidiabetic drugs | |
| NO324534B1 (no) | Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |